Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, Tomasson MH, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Gasparetto C, Chu MP, Dalovisio A, Sebag M, Lesokhin AM. Bahlis NJ, et al. Among authors: dholaria b. Nat Med. 2023 Oct;29(10):2570-2576. doi: 10.1038/s41591-023-02589-w. Epub 2023 Oct 2. Nat Med. 2023. PMID: 37783970 Free PMC article. Clinical Trial.
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall AC, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS. Costa LJ, et al. Among authors: dholaria br. Lancet Haematol. 2023 Nov;10(11):e890-e901. doi: 10.1016/S2352-3026(23)00236-3. Epub 2023 Sep 27. Lancet Haematol. 2023. PMID: 37776872 Clinical Trial.
TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Marvin-Peek J, Mason EF, Kishtagari A, Jayani RV, Dholaria B, Kim TK, Engelhardt BG, Chen H, Strickland S, Savani B, Ferrell B, Kassim A, Savona M, Mohan S, Byrne M. Marvin-Peek J, et al. Among authors: dholaria b. Transplant Cell Ther. 2023 Jun;29(6):390.e1-390.e10. doi: 10.1016/j.jtct.2023.03.008. Epub 2023 Mar 9. Transplant Cell Ther. 2023. PMID: 36906277 Free article.
Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission.
Nagler A, Labopin M, Dholaria B, Blaise D, Bondarenko S, Vydra J, Choi G, Rovira M, Reményi P, Meijer E, Bulabois CE, Diez-Martin JL, Yakoub-Agha I, Brissot E, Spyridonidis A, Sanz J, Patel A, Arat M, Bazarbachi A, Bug G, Savani BN, Giebel S, Ciceri F, Mohty M. Nagler A, et al. Among authors: dholaria b. Br J Haematol. 2023 Jun;201(6):1169-1178. doi: 10.1111/bjh.18765. Epub 2023 Mar 22. Br J Haematol. 2023. PMID: 36949658
Emerging therapeutic agents for lung cancer.
Dholaria B, Hammond W, Shreders A, Lou Y. Dholaria B, et al. J Hematol Oncol. 2016 Dec 9;9(1):138. doi: 10.1186/s13045-016-0365-z. J Hematol Oncol. 2016. PMID: 27938382 Free PMC article. Review.
Cancer immunotherapy beyond immune checkpoint inhibitors.
Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y. Marin-Acevedo JA, et al. Among authors: dholaria b. J Hematol Oncol. 2018 Jan 12;11(1):8. doi: 10.1186/s13045-017-0552-6. J Hematol Oncol. 2018. PMID: 29329556 Free PMC article. Review.
100 results